HR and breast carcinoma: In addition, 69.0% (180/261, 95%CI: 63.0%–74.5%) modified N0 and 98.1% (203/207, 95%CI: 95.1%–99.5%) modified N1 patients with HR+/HER2‐, early‐stage breast cancer received chemotherapy (Figure 2).